Trial Profile
Safety and efficacy of exenatide as monotherapy and adjunctive therapy to oral antidiabetic agents in adolescents with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 20 Apr 2020 Status changed from active, no longer recruiting to completed.
- 14 Jan 2020 Planned End Date changed from 6 Mar 2023 to 22 Jun 2021.
- 14 Jan 2020 Status changed from suspended to active, no longer recruiting.